AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$JAZZ

McSharry Heather Ann sold $482K of JAZZ

McSharry Heather Ann sold 2,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $241.00 ($0.48M total) on 2026-05-22.

Original reporting
SEC EDGAR · McSharry Heather Ann
Published May 27, 2026, 10:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JAZZ
Neutral
medium confidence
Mentioned
$JAZZ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JAZZNeutralLow
01

Why it matters

Treat as a sentiment/positioning datapoint rather than a fundamental catalyst; monitor for subsequent insider buys/sales or earnings/guidance changes.

02

Market read

A single director sale (~$482k) may slightly weigh on sentiment, but without corroborating company news the trading impact should be muted.

03

What to watch

No 10b5-1 plan is cited; however, Form 4s often reflect non-informational motives, and the article provides no context on prior buying/selling patterns.

Relevance 6/10Timing: Immediate (today’s filing) but expected to have limited follow-through absent additional catalysts.

Background

SEC Form 4 reports insider transactions; this filing documents a director’s open-market sale of Jazz Pharmaceuticals shares.

Company-level read

Ticker impact

$JAZZNeutralMedium confidence
Context

Jazz Pharmaceuticals director Heather Ann McSharry filed an open-market sale of 2,000 shares at $241/share for ~$482k, disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless follow-on disclosures or fundamentals change.

Evidence & confidence

The filing is a routine director sale (no 10b5-1 plan stated) with modest size relative to typical liquidity; without accompanying company news, directional inference is weak.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory catalyst.

Regional

None indicated; disclosure is US SEC EDGAR and does not reference regional operations.

Global

None indicated; no international deal/regulatory event mentioned.

Counterpoint

What could challenge this read

The sale may reflect diversification, tax planning, or scheduled liquidity needs rather than a negative view on Jazz fundamentals.

Key entities

  • issuer
    Jazz Pharmaceuticals plc

    Subject of the SEC Form 4 insider transaction disclosure.

  • director
    Heather Ann McSharry

    Director who sold 2,000 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JAZZ insider trading history →

Related articles

SEP 4
$JAZZHighAI 9/10

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

insidermonkey.com3 min
SEP 2
$JAZZMedAI 8/10

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.

finance.yahoo.com2 min
SEP 2
$JAZZHighAI 8/10

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced that zanidatamab plus chemotherapy showed improved overall survival in HER2+ advanced GEA patients compared to trastuzumab, per HERIZON-GEA-01 trial results. The HR for OS improved with longer follow-up. The FDA approved zanidatamab in August 2026 for first-line treatment, supported by earlier trial data. Jazz plans to present updated data at a medical meeting and submit findings to global health authorities.

cancernetwork.com2 min
AUG 31
$JAZZMedAI 8/10

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) shares rose 2.5% after positive Phase 3 trial results for Ziihera combined with chemotherapy in advanced gastroesophageal adenocarcinoma. The trial showed a statistically significant overall survival benefit, reinforcing the drug's potential. The stock closed at $250.79, up 2.6% from the previous close. JAZZ is up 44.8% year-to-date and near its 52-week high of $261.62.

financialcontent.com2 min
AUG 31
$JAZZHighAI 8/10

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (JAZZ) reported that Ziihera, combined with chemotherapy, showed statistically significant overall survival benefits in a Phase 3 trial for HER2+ advanced gastroesophageal adenocarcinoma (GEA). The results support Ziihera as a new standard of care, following its recent FDA approval. The company plans to present the data at a major medical meeting in Q4 2026.

prnewswire.com2 min